Recruiting studies: Egfr Mutated Locally Advanced Or Metastatic Nsclc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
Phase 1 · 1 location(s) · National Cancer Center, China · NCT06362980 To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Lo
Phase 2 · 7 location(s) · OBI Pharma, Inc · NCT05442060 DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Phase 1/Phase 2 · 1 location(s) · Dizal Pharmaceuticals · NCT07070440 Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2 · 26 location(s) · Teligene US · NCT05168566 A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
Phase 2 · 5 location(s) · Abbisko Therapeutics Co, Ltd · NCT06668103 Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366 Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation
Phase 3 · 2 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07416994 Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Li
Phase 3 · 78 location(s) · ArriVent BioPharma, Inc. · NCT07185997 Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Phase 3 · 2 location(s) · Allist Pharmaceuticals, Inc. · NCT06956001 A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Trea
Phase 1/Phase 2 · 5 location(s) · Henan Genuine Biotech Co., Ltd. · NCT07231068 Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced
Phase 3 · 166 location(s) · AstraZeneca · NCT06350097 A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Pos
Phase 2 · 34 location(s) · RemeGen Co., Ltd. · NCT06962865 An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Pat
Phase 4 · 39 location(s) · AstraZeneca · NCT07357597 A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, f
Phase 2 · 202 location(s) · Janssen Research & Development, LLC · NCT06667076 A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT07058519 A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR
Phase 2 · 80 location(s) · Taiho Oncology, Inc. · NCT05967689 Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06517953 Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expressi
Phase 1/Phase 2 · 1 location(s) · Second Affiliated Hospital of Nanchang University · NCT07655622 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doub
Phase 3 · 303 location(s) · AstraZeneca · NCT06417814 DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
Phase 2 · 1 location(s) · Dizal Pharmaceuticals · NCT06276283 First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer H
Phase 1/Phase 2 · 24 location(s) · Pierre Fabre Medicament · NCT06043817 A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With
Phase 2/Phase 3 · 53 location(s) · AbbVie · NCT07005102 Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation
Phase 1 · 12 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT06050980 A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Particip
Phase 3 · 285 location(s) · Bayer · NCT06452277 Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
Phase 3 · 2 location(s) · TYK Medicines, Inc · NCT05382728 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherap
Phase 2/Phase 3 · 110 location(s) · AbbVie · NCT07155187 Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
Phase 3 · 1 location(s) · Peking Union Medical College Hospital · NCT06674343 Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）
Phase 3 · 1 location(s) · CSPC Megalith Biopharmaceutical Co.,Ltd. · NCT06927986 A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced o
Phase 3 · 1 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07183189 A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
Phase 1/Phase 2 · 5 location(s) · Avistone Biotechnology Co., Ltd. · NCT07538804

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.